Medical technology company Medtronic has teamed up with Samsung Electronics to improve diabetes management for patients living with the disease.
The two companies are to combine their resources to develop a range of solutions that strive to enhance the way people with diabetes live, including remotely viewing diabetes data and integrating mobile and wearable devices into diabetes management systems.
Announced at the American Diabetes Association’s 75th Scientific Sessions, the alliance will utilise Samsung’s knowledge of consumer mobile technology to deliver access to Medtronic’s integrated diabetes management systems that provide outcomes proven in clinical stages.
Alejandro Galindo, VP and general manager of the intensive insulin management business at Medtronic, said: “By addressing more of the social and emotional aspects of living with diabetes and improving lifestyle fit, we believe that more people worldwide will be able to experience better diabetes control that today’s advanced therapies provide.
“Our partnership with Samsung is a key step in providing convenient and discreet access to diabetes data, so together we can provide people with diabetes greater freedom and better health.”
The partnership’s first project will focus on delivering more discreet and convenient access to personal diabetes data by developing an app to view insulin pump and continuous glucose monitoring (CGM) information.
The app will work with Medtronic’s MiniMed Connect product and it expected to be available later this year.
Dr David Rhew, CMO and head of healthcare and fitness for Samsung Electronic America, sad: “Patients are seeking better ways not only to monitor their condition, but also to enjoy a greater quality of life.
“We are excited to partner with Medtronic to develop diabetes management solutions that produce positive change and greater autonomy for people living with diabetes.”
Last year, Sanofi launched their own diabetes app for children and carers on which users could participate on the gaming offering to learn more about type 1 of the disease. In addition to this, Sanofi also worked with Medtronic to develop drug device combinations for patients with type 2 diabetes.
